Insulet (Nasdaq:PODD) issued an SEC filing confirming that Charles Alpuche, executive vice president and chief operating officer, intends to retire.
Alpuche informed the company of his decision to retire on Dec. 13. His retirement takes effect on Dec. 31, 2022.
The Acton, Massachusetts-based automated insulin delivery technology developer promoted Prem Singh as a result. Singh currently serves as VP and head of global supply chain operations at Insulet. He takes over as SVP, global operations, effective Jan. 1, 2023.
According to a news release, Alpuche agreed to remain with Insulet from Jan. 1, 2023, through April 1, 2023. He intends to assist with the transition of responsibilities to Singh.
This marks the second executive departure at Insulet this year. In May, CEO Shacey Petrovic stepped down due to personal reasons. Former ResMed executive Jim Hollingshead took over the corner office.
In the meantime, Insulet made major strides in 2022 around its next-generation Omnipod 5. It became the first tubeless, wearable automated insulin delivery system cleared for marketing in the U.S. in January. Since, it received both FDA approval and CE mark approval for children two years old and up.